Phase 3 Breast Cancer Trial, Recruiting NCT06419621 Sponsor: Biotheus Inc. Condition: Breast Cancer
Back to Breast Cancer

Phase 3 Breast Cancer Trial, Recruiting

NCT06419621
Recruiting Phase 3

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are able to understand the study information and are willing to sign a written consent form and follow the study schedule and procedures
  • Women between 18 and 70 years of age (inclusive)
  • People with a laboratory-confirmed diagnosis of breast cancer that cannot be surgically removed, has spread locally, or has spread to other parts of the body, and whose cancer tests negative for estrogen receptor (ER), progesterone receptor (PR), and HER-2 (commonly called triple-negative breast cancer)
  • People who have not previously received systemic drug treatment (other than hormone therapy) for advanced breast cancer, OR people who did receive taxane-based chemotherapy before or after surgery, as long as the cancer came back or spread at least 12 months after that treatment ended
  • People whose general physical functioning is rated 0 or 1 on a standard medical activity scale, meaning they are fully active or have only minor limitations in physical activity
  • People with a life expectancy of at least 12 weeks
  • People who have at least one tumour that can be measured on a scan according to standard criteria (confirm with trial site for specific details about which lesions qualify)

Who may not be able to join:

  • People who have previously been treated with certain immune-boosting or immune-checkpoint drugs (such as CTLA-4, PD-1, PD-L1, or LAG3 inhibitors, or CD137 agonists), or with drugs that target blood vessel growth (anti-VEGF therapies)
  • People who have brain or spinal cord metastases that are not controlled or are causing symptoms
  • People who have had another active cancer within the past 5 years, unless that cancer was treated locally and is considered fully cured
  • People with poorly controlled high blood pressure (readings of 140 mmHg or higher for the top number, and/or 90 mmHg or higher for the bottom number)
  • People with a history of a hypertensive crisis or a condition called hypertensive encephalopathy (a severe complication of very high blood pressure)
  • People who have had an abnormal passage or hole in the abdomen, between the throat and oesophagus, in the digestive system, or an internal abdominal infection within the past 6 months
  • People who still have side effects from previous cancer treatments that have not reduced to a mild level or resolved, based on standard medical grading criteria
  • People with fluid build-up around the lungs, heart, or abdomen that cannot be controlled
  • People who have previously received a stem cell transplant from a donor or an organ transplant

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Principal Investigator: Jiong Wu, professor, Fudan University

Phone: +86 13810452270

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 3
Sponsor
Biotheus Inc.
Registry
ClinicalTrials.gov
Start date
11 June 2024
Est. completion
1 July 2027

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Progression-Free Survival (PFS) assessed by Blinded Independent Review Committee (BIRC); Overall Survival (OS)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov